NCT06490081View on ClinicalTrials.gov

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

June 30, 2026

Conditions
Myelosuppression
Interventions
DRUG

Trilaciclib

During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER